Helicobacter hepaticus cDNA and Antigen

Helicobacter hepaticus is a gram-negative bacterium that colonizes the liver and intestinal tract of mice, and is associated with chronic hepatitis, liver cancer, and inflammatory bowel disease in these animals. Several antigens of H. hepaticus have been identified as potential targets for vaccine development and immunotherapy, including P15HH28, P21Hh7, P31HH29, and P44Hh9.

P15HH28 is a surface-exposed protein that has been shown to be involved in bacterial adhesion and invasion of host cells. Antibodies against this protein have been shown to reduce bacterial colonization and inflammation in infected mice, indicating its potential as a target for vaccine development and immunotherapy.

P21Hh7 is a lipoprotein that is involved in bacterial colonization and persistence in the liver. This protein has been shown to induce a strong humoral immune response in infected mice, and antibodies against it have been shown to confer protection against H. hepaticus infection.

P31HH29 is a major outer membrane protein of H. hepaticus that is involved in bacterial adhesion and colonization. Antibodies against this protein have been shown to reduce bacterial load and inflammation in infected mice, indicating its potential as a target for vaccine development and immunotherapy.

P44Hh9 is a flagellar protein that is involved in bacterial motility and colonization. This protein has been shown to induce a strong cellular immune response in infected mice, and T cells specific to this protein have been shown to confer protection against H. hepaticus infection.

These antigens of H. hepaticus have shown promise as targets for developing new therapies and vaccines against this bacterial pathogen. However, further research is needed to fully understand their mechanisms of action and to optimize their use in therapeutic and diagnostic applications. Ultimately, a better understanding of the role of these antigens in H. hepaticus infection could lead to improved prevention, diagnosis, and treatment of diseases associated with this bacterial pathogen in mice.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

Helicobacter hepaticus cDNA and recombinant antigen can be used in mice to induce an immune response against Helicobacter hepaticus. Mice can be immunized with Helicobacter hepaticus cDNA or recombinant antigen to generate an immune response against this pathogen. This immune response can then be studied to gain insight into the pathogenesis of Helicobacter hepaticus infection in mice. Additionally, this approach may be useful for the development of vaccines and other therapeutic strategies against Helicobacter hepaticus infection.